TrialVaccine2016

A first-in-human phase 1 trial to evaluate the safety and immunogenicity of the candidate tuberculosis vaccine MVA85A-IMX313, administered to BCG-vaccinated adults.

Alice Minhinnick et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.